Kick off the new year with the new unified search on ScienceOpen! We have accomplished a lot over the last year and are looking forward to supporting the academic community in 2017.
In 2016 ScienceOpen brought you more context: Now your search comes with a new analytics bar that breaks down your search results by collections, journals, publishers, disciplines, and keywords for quicker filtering. Try a search for the pressing topics of 2016 like Zika or CRISPR and take the new features for a spin.
Researcher output, journal content, reference lists, citing articles can all be dynamically sorted and explored via Altmetric score, citations, date, activity. Statistics for journals, publishers and authors give overview of the content that we are indexing on ScienceOpen. Check out the most relevant journals on ScienceOpen, for example BMC Infectious Diseases or PloS Genetics for a new perspective. Or add your publications to your ORCID and get a dynamic view of your own output.
In 2016 ScienceOpen brought you more open: The ScienceOpen team participated in and helped organize numerous community events promoting Open Science. From Peer Review Week to OpenCon, talks at SSP in Vancouver and SpotOn in London, our team was on the road, debating hot issues in scholarly communication.
In order to bring more visibility to smaller community open access journals, very often with close to non-existent funding and run on a voluntary basis, we launched our platinum indexing competition. It was geared towards open access journals charging no APCs to their authors. Four successful rounds in, we have selected 18 journals to be indexed and awarded some of them with special featured collections on the ScienceOpen platform. This activity was particularly rewarding as we heard back from journals’ editors expressing their enthusiasm about the ScienceOpen project and enjoying bigger usage numbers on their content.
The ScienceOpen 2.017 version will continue to focus on context, content and open science. We are your starting point for academic discovery and networking. Together let’s explore new ways to support visibility for your publications, promote peer review, improve search and discovery and facilitate collection building. Here is to putting research in context! The year 2016 had some great moments – may 2017 bring many, many more!
Open Access Week is the annual event to show our global support for all things open access! The theme this year is all about committing to putting open into action in order to take real steps towards open scholarship and supporting a stronger research framework.
SPARC have created an action portal of various activities you can undertake this week to help yourself and your colleagues support open access. These are:
Make a list of open access journals in my discipline I would consider publishing in and share it with colleagues.
Start a conversation about Open Access during a research group meeting, journal club, or staff meeting.
Open Access is not a research issue. It’s not a European issue. It’s not a publisher or policy issue. Open Access is a global issue.
Knowledge is a public good, and forms the basis of an environment in which everyone can develop and build inclusively. It can help to inspire publication innovation and entrepreneurship. Open Access to research sits at the core of this on a global level.
As part of our ‘Open Science Stars’ series, we’ve been trying to expose some of the views and experiences of people from the world of open around the world. This global perspective is important, because researchers have a responsibility to contribute to the open sharing of results around the world, and not take a free ride based on elite privilege.
Open Access and China
Today, we wanted to delve a bit into the status of OA in China. Recently, we partnered with Higher Education Press, one of the top publishers in China, to index one of their flagship journals, and to demonstrate China’s continued support for more open research practices. China has committed to rapid growth in scientific research and development recently, and this is reflected in the solid evidence for a strongly developing open access research base.
Free to publish Open Access journals offer an incredible service to the research community and broader public, with editors often working long hours with no compensation. We want to recognise this effort and reward it with free indexing on our platform!
More visibility for your journal
Journals indexed on ScienceOpen:
Reach new audiences and maximize your readership
Drive more usage to your journals
Upload your content to a unique search/discovery and communication platform
Open up the context of your content
What do we need from you?
An application form can be found here. Fill it out, and submit to our team. Simple!
On the last day of every month, we will select and announce the winners via social media, and begin the next cycle! Out of the applicants, we will select up to 10 journals per month for free indexing, and the best application will get a free featuredjournal collection too! All others will roll over into the next month.
At ScienceOpen, you can peer review any of 13 million research articles (and climbing every day!). That’s right! Any one you want. Even if an article has been published and ‘passed’ peer review, you can still comment on it. The only reason there would ever be no value in doing this would be if all published work were completely infallible, which is clearly not the case.
The ScienceOpen community has agreed to only allow formal peer reviews from ScienceOpen members that have published at least 5 articles in peer reviewed journals. For this reason, please do not forget to add your publication history on ORCID. Only if you do not have an ORCID account can a peer review manager at ScienceOpen set up an account for you. If you would like for someone to do this, please send an email to firstname.lastname@example.org before proceeding. Put the phrase “Create accounts” in the subject line, and put your name and email address in the body of the email.
Context is something we’ve been thinking a lot about at ScienceOpen recently. It comes from the Latin ‘con’ and ‘texere’ (to form ‘contextus’), which means ‘weave together’. The implications for science are fairly obvious: modern research is about weaving together different strands of information, thought, and data to place your results into the context of existing research. This is the reason why we have introductory and discussion sections at the intra-article level.
But what about context at a higher level?
Context can defined as: “The circumstances that form the setting for an event, statement, or idea, and in terms of which it can be fully understood.” Simple follow on questions might be then, what is the context of a research article? How do we define that context? How do we build on that to do science more efficiently? The whole point for the existence of research articles is that they can be understood by as broad an audience as possible so that their re-use is maximised.
There are many things that impinge upon the context of research. Paywalls, secretive and exclusive peer review, lack of discovery, lack of inter-operability, lack of accessibility. The list is practically endless, and a general by-product of a failure for traditional scholarly publishing models to embrace a Web-based era.
ScienceOpen Collections are thematic groups of research articles that transcend journals and publishers to transform how we collate and build upon scientific knowledge.
What are Collections
The modern research environment is a hyper-dimensional space with a vast quantity of outputs that are impossible to manually manage. You can think of research like a giant Rubik’s cube: you have different ‘colours’ of research that you have to mix and match and play around with to discover how the different sections fit together to become something useful.
We view Collections as the individual faces of a Rubik’s cube. They draw from the vast, and often messy, pool of published research to provide an additional layer of context and clarity. They represent a new way for researchers to filter the published record to discover and curate content that is directly relevant to them, irrespective of who published it or what journal it appears in.
Advantages of Collections
Perhaps the main advantage of Collections to researchers is that they are independent of journals or publishers and their branding criteria. Researchers are undoubtedly the best-placed to assess what research is relevant to themselves and their communities. As such, we see Collections as the natural continuing transformation of the concept of the modern journal, acting in almost full cycle to return them to their basic principles.
The advantage of using Collections is that they provide researchers with the power to filter and select from the published record and create what is in essence a highly-specialised virtual journal. This means that Collections are not pre-selective, but instead comprise papers discriminated only by a single criterion: research that is relevant to your peers, and also deemed relevant by them.
Filtering for Collections occurs at different levels depending on scope or complexity of research. For example, Collections can be designed to focus on different research topics, lab groups or research groups, communities, or even departments or institutions. Collections can also be created for specific conferences and include posters from these, published on ScienceOpen. Youdefine the scope and the selection criteria.
Two days ago, the World Health Organisation declared that the threat of the Zika virus disease in Latin America and the Caribbean constituted a Public Health Emergency of International Concern.
The decision was based on the outbreak of clusters of microcephaly and Guillian-Barré syndrome, which are devastating cases of congenital malformation and neurological complications. While a direct causal relationship has yet to be formally stated, the correlation between Zika infection during pregnancy and microcephaly is strongly correlated.
At ScienceOpen, we believe that rapid publication serves the communication of research, and aim to have submitted papers published online within 24-48 hours. For articles relating to the Zika outbreak, we are waiving the usual submission charge, and any published articles will be integrated into our pre-existing research collection on the Zika virus. Articles will receive top priority, and therefore be almost immediately available to the research community, medical professionals, and the wider public. We encourage submission of all articles relating to the virus. Please directly contact Stephanie Dawson for submissions and related enquiries.
There is clearly a need to co-ordinate international efforts, including those of the research community, to investigate and understand the Zika virus better. At ScienceOpen, we want to play our part in facilitating the communication of any such research, and the speedy protection of those at risk. We are happy to join other open access publishers such as F1000 Research and PLOS Current Outbreaks (both of which which publish very rapidly) who have similarly declared that all research published with them on the Zika virus can be published free of charge.
I wrote this post on the plane back from my trip to Shanghai after a multiple day delay that (looking on the bright side) allowed me to see some of the sights courtesy of Hainan Airways!
I was invited to speak at the 3rd International Academic Publishing Forum on August 19th. Organized by the Shanghai Jiao Tong University press, the event brought together nearly 60 Chinese University Presses and representatives from some Western academic publishers – Elsevier, Wiley, Springer, Sage, Brill and ScienceOpen –to discuss what we can learn from one another.
My most powerful impression was the high value China places on knowledge. Mr. Shulin Wu, Vice-Chairman of the Publishers Association of China said in his in his keynote speech that the government regards “knowledge production to be as important as mining or oil”. And China is set to surpass both the US and the EU in spending on research and development by 2020. Communicating this knowledge, therefore, also has a high priority and falls mainly to the university presses. Their main short-term goals expressed over the two days were internationalization and digitalization of their content, with language seen as the main hurdle. Certainly all had a plan for going global.
But some publishers, including myself, were already thinking beyond internationalization and digitalization to the next step in academic publishing. Jason Wu hit the nail on the head by describing Wiley’s process of transformation “from publishing business to global provider of knowledge and learning services.” Solutions for researchers must be digital, global, mobile, interdisciplinary (Bryan Davies of Elsevier quoted a study that found 44% of researchers look for information outside of their own field). And Open Access is a good place to start.
The Open Access business model for journal publishing is perfect for Chinese publishers who have until now been dependent on cooperation with Western publishers to get their authors heard. Chinese scientists who do world-class research can publish in “world-class” journals such as Science or Nature, but publishers here were asking the hard question of themselves – why are so few of those world-class journals published in China? While Open Access cannot itself address the problem of reputation, it can insure that research can be read immediately and globally, without a team of sales representatives on every continent. As essentially non-profit entities with a mission to communicate China’s research successes to the world they are uniquely situated. With access to so much outstanding research, I sincerely hope that Chinese publishers will embrace this opportunity.
Taking the Shanghai subway I can attest that young Chinese are constantly networking on their mobile devices. A scientific networking and research platform like ScienceOpen in China would have a good chance to catch the imagination of young scientists. But time will tell how open this generation will be allowed to be. During my stay the Chinese government shut down up to 50 online news websites and nearly 400 Weibo and WeChat accounts for spreading “rumours” of the recent chemical explosion which took 129 lives. Twitter, Facebook, Google and many other sites were blocked during my visit, which left me feeling rather cut off from the rest of the world.
It was a crazy week – from the crowds and flashing neon of Shanghai to the peaceful magnificence of the Great Wall. I came away with a sense of the huge potential in China and the feeling that China needs Open Access and the Open Access movement needs China.
Every year in May, I attend the Charité Entrepreneurship Summit, a unique event for international medical entrepreneurs and life science innovators organized by the Charité Foundation in Berlin. This ‘think-tank’ meeting connects sparkling ideas with pragmatic reality and facilitates a ‘one-of-a-kind’ scene for ‘let’s innovate and implement’ biomedical professionals and entrepreneurs from all over the world. This year, I had a special opportunity to meet and conduct an interview with Dr. Anula Jayasuriya, a wonderful personality and a talented scientist, physician, and investor. While contacting and talking with Anula Jayasuriya, I realized that she represents an amazing role model for every young scientist-entrepreneur. Here is some of food for thought from our conversation on entrepreneurship in medical sciences and open science.
Q1: The NIH has been one of the biggest forces behind the push towards increasing access to scientific information, but we are just at the beginning of the open science movement – open data being the next big hurdle. Do you see potential for an impact on the US health care system?
AJ: I think the NIH initiatives are very exciting, and open data will make a huge difference in the whole US health care system – but it will take time. At the end of the day, the NIH doesn’t make drugs, right? So we have to contend with industry. I wonder how it’s going to play out for pharma and biotech? Their business model is centered on protecting their innovations with IP and making money from products during the exclusivity period.
The moral imperative to share drug development data is that such information would greatly benefit patients and society. Let’s speculate that three big pharma companies working on development of the same category of drugs in their pipelines would be willing to share their failure results. This would be very important in preventing adverse reactions and health-related complications in patients. Perhaps these companies could form an industry consortium where every company was required to share their drug development failure data. There are many hurdles to be overcome before this can be a reality. For example, the first to fail is likely to benefit others but not itself. Money saved by averting future failures maybe eclipsed by lost revenues and compromised IP, etc. Pharma has to see an economic incentive to share data. Perhaps there could be an attractive market for acquiring failure information? In any case, there would need to be a dramatic transformation and innovation around the existing IP-based “winner-take-all” industry business model.
Pharma has to see an economic incentive to share data
Q2: Do you believe that patient access to the clinical trial data and mandated data sharing will create a climate that could accelerate drug development and translational science research?
AJ: I believe that the biggest motivator and catalyst in this process of sharing clinical trial information will be the patient. We are entering a very exciting era of patient engagement. Going forward, I see patients playing active roles in clinical trials. As patient participation is essential to clinical drug development patients have the power to make the change. The passive patient is likely to become a memory of the past. Already today there is a US Government funded institute called PCORI (Patient Centered Outcomes Research Institute) that is making grants to investigators who engage patients in clinical trial design. I see patients challenging Pharma, Biotech and Regulators to adapt to a world where patients are active decision makers alongside industry and regulators. The FDA today is caught in the middle of a rapidly transforming ethos. All stakeholders will need to adapt to a new equilibrium. Let me give you some examples. In 1993, I was working for Roche pharmaceuticals. This was during the early days of the HIV outbreak where there was an urgent need to develop new drugs to fight the devastating epidemic. Patient advocacy groups had a huge impact on getting pharma companies to work together and also influenced the FDA to act quickly and really make a difference (read more about Act Up). I saw first-hand how powerful the cooperative approach was. By the way, physicians were very pleased to see collaborations, which led to effective treatment and greatly benefited patients. But that was one narrow case in the past.
Today, I see changes taking place across several diseases, especially in fighting cancer and rare diseases. Patients, together with their families, are building tight communities to share and disseminate knowledge about their diseases. In the USA, there is a popular movement called “hacking your body”. This is a different kind of open innovation – the innovations are ones that have been “opened”/discovered by patients. The drive is coming from patients and their families. Now, patients are playing active roles, often going around regulatory barriers and industry specifications and advocating for themselves. As a physician, I am immensely pleased to see engaged patients. There are likely to be some hiccups and missteps along the way but I think that in the long run it will lead to accelerated drug development and, most importantly, better patient outcomes.
I believe that the biggest motivator and catalyst in this process of sharing clinical trial information will be the patient… This is a different kind of open innovation – the innovations are ones that have been “opened”/discovered by patients.
In the US, patients are entitled to free access to their medical records. If patients who participated in clinical trials were also entitled to access to their clinical trial records and were able to communicate with co-participants in the same trial I think they could “hack” the trial, by comparing adverse events and outcomes. And they are likely to share these aggregated data openly even if industry does not. I see patients, their families and society as the key actors in improving their health care.
There are two important ways to improve and accelerate drug development: understanding the science behind drug failures, and developing a process of sharing information openly within trial participant and disease the communities through the internet.
It is very encouraging that the NCI (the National Cancer Institute (NCI), part of the US National Institutes of Health) has successfully mediated a unique public-private partnership called the lung map trial, a multi-pharma collaboration in lung cancer. Five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune) and Foundation Medicine (a cancer tumor genome analytics company) will collaborate to provide the treatment that is best suited to the individual patient – delivering personalized care. Patients need to enroll only in a single trial to access drugs developed by five different pharma companies. This is a groundbreaking development – real progress.
In addition, there are many digital health start-up companies whose business models are based on selling anonymized clinical trial data. (Of course, there are several ethical, privacy and compliance considerations to be addressed, but let’s just put them aside for now.) The promise of “Big Data Analytics” as it applies to health care is that the aggregation of these data will lead to better outcome for patients. I am optimistic!
There are two important ways to improve and accelerate drug development: understanding the science behind drug failures, and developing a process of sharing information openly within trial participant and disease the communities through the internet.
Q3: Do you think that big data, open science, and a worldwide network could in the future precisely tailor therapies to each patient’s individual requirement?
AJ: Precision medicine is the holy grail of health care. Tailoring cancer therapies makes a big difference in treatment outcomes today – cancer is the “low hanging fruit” due to easy access to the genomic analyses of tumors. Ultimately, delivering precision medicine relies on aggregating and analyzing data on a large number of areas: genomics, metabolomics, RNA, proteomics, behavior, environmental exposures, social and cultural milieus, etc. – this is a VERY big data play. I think the delivery of precision medicine will happen incrementally, in stages – with ever increasing degrees of precision as our understanding of the various contributing areas increase. Open science and data sharing are essential to generating the best data inputs from a multitude of sources to create a big data repository that serves as the basis for analytics.
Open innovation enables us to create products from a platform (repository) of information, which is freely available to everybody. For instance, having unrestricted access to scientific literature enables a company to develop their own algorithms for novel prognostic and diagnostic genomic screens – they could, for example, figure out which patients are sensitive/resistant to various drugs. Algorithms “learn” — the more patient data tested, the more an algorithm is refined and hence clinically informative. If, however, a company develops a screening or diagnostic test and patents it, thus excluding its use by others, it is no longer “open”.
The case of Myriad Genetics Inc. is interesting. They recently lost a lawsuit contesting the exclusivity of their BRCA test for breast cancer. The company used patient sequence information to develop and patent their screening test. Myriad claimed that they had exclusive rights to patients’ sequence information and to the test they derived from it. For several years Myriad was able to build a very profitable business by excluding others from duplicating their test, even though the actual sequence information the company used belonged to patients (http://www.the-scientist.com/?articles.view/articleNo/36076/title/Gene-Patents-Decision–Everybody-Wins/). Myriad’s claims were overturned and patent law is the US changed such that naturally occurring sequences can no longer be patented. I am in favor of this outcome as it greatly benefits patients who can now access BRACA tests from several companies at a much lower price.
I am excited about the concept of open innovation because it is a major step toward improving patient care. That being said, in a capitalist society, this has to be tempered by providing sufficient incentives to industry (on whom we are dependent unless we innovate a new model) to produce drugs, diagnostics, etc. I am confident that the “new normal” will result in better health care for society and the ability of industry to adapt and innovate novel and more productive business models.
I thank Dr. Anula Jayasuriya for the fascinating insights into the world of drug discovery and the role open innovation can play.